Iovance Biotherapeutics stock narrows lung cancer trial strategy

Published on 10/30/2026 at 20:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Iovance Biotherapeutics stock faces a narrower lung-cancer strategy after updated lifileucel data. Enrollment in a biomarker-selected cohort is due in November.

Strategy shifts toward selected patients

Updated lifileucel data showed a 24.6 percent response rate in 69 patients with advanced nonsquamous lung cancer.
Iovance plans to begin enrolling a biomarker-selected POSITILITY cohort in November 2026.
The company still targets a supplemental biologics license application for the broader population in 2027.

IOVA, US4622601007, Illustration mit AI erstellt.

Iovance Biotherapeutics reported updated data from its IOV-LUN-202 study on Thursday, October 29, 2026, with lifileucel showing a 24.6 percent objective response rate in 69 patients with nonsquamous metastatic non-small cell lung cancer. BioMed Nexus reported that the result was consistent with the previously reported interim rate and that Iovance is narrowing its registration strategy toward a biomarker-selected group.

Iovance Biotherapeutics stock traded at 7.56 euros on Lang & Schwarz at 8:09 p.m. CEST on Friday, October 30, 2026. Investors can follow the real-time quote of Iovance Biotherapeutics stock.

Biomarker selection reshapes development plan

The October 14 data cutoff covered 69 treated patients. Seventeen patients responded, including 15 confirmed responses and two unconfirmed partial responses awaiting confirmation. The company described safety findings and duration-of-response information as consistent with earlier reports, according to the published briefing.

A retrospective analysis found a 43.3 percent response rate among 30 patients with KRAS wild-type tumors, compared with 11.4 percent among 35 patients with KRAS mutations. A smaller subgroup combining KRAS wild-type status, HER2 wild-type status and current or former smoking history recorded a 59.1 percent response rate in 22 patients.

November enrollment sets next milestone

Iovance plans to start enrollment in November 2026 for POSITILITY, a prospective biomarker-enriched cohort within IOV-LUN-202. The selection approach uses KRAS status, HER2 status and smoking history, and the company intends the cohort to support a potential registration pathway subject to FDA feedback.

The company also plans a supplemental biologics license application for the broader nonsquamous population in 2027, based on a final dataset of roughly 80 patients. A frontline study in the enriched population is planned for 2027.

U.S. biotechnology shares remain sensitive to clinical readouts and regulatory milestones; follow current S&P 500 market reports for the wider market setting.

More developments can be found in more news and analyses on Iovance Biotherapeutics stock.